MonoSol Rx Announces Hiring of Larry W. Kranking as Senior Vice-President, Pharmaceutical Operations

Warren, NJ and Portage, IN – FOR IMMEDIATE RELEASE - MonoSol Rx announced today the hiring of Larry W. Kranking as its new Senior Vice President Pharmaceutical Operations located in Portage, IN.

Mr. Kranking brings to MonoSol Rx over 30 years of diverse pharmaceutical manufacturing and business leadership experience essential to the current and future growth needs of the company.

In his most recent position, Larry was President of Lang Medikaments, Inc. where he led a contract manufacturing company focused on the production of sterile ophthalmic and parenteral products.

Prior to that, from 1996-2004, Larry was employed with Esai Inc., RTP, NC where he successfully managed the design, construction, qualification and FDA approval of their parenteral and solid dose drug development and commercial operations facility. During his 8 years at Eisai, Larry was given increasing levels of responsibility culminating into the position of Vice President and General Manager.

Before his employment with Eisai, Larry worked 16 years for Boehringer Ingelheim Pharmaceuticals, Inc. where, during his tenure, he held positions of increasing responsibility starting as a Production Supervisor and ultimately named Director of Production Operations in their Pharmaceutical Operations Department.

Larry was a board member of the International Society of Pharmaceutical Engineering (ISPE) from 1989-1998 and held the position of President from 1996-97. In 1998, while a member of the ISPE, he received their highest recognition award, The Richard Purdy Distinguished Achievement Award. He was also Chairman of the SUPAC Committee for the FDA and ISPE. Larry’s work on SUPAC earned him an FDA Special Recognition Award in 1997 “for invaluable service and commitment to the American public by providing technical support to the U.S. Food and Drug Administration in the development of the SUPAC-IR Equipment Guidance”. Additionally, Larry is the past Chairman of the Advisory Board of Pharmaceutical Engineering Program at Columbia University.

“Larry brings to MonoSol Rx the necessary leadership skills and pharmaceutical experience to lead our commercial operations in Portage, Indiana. We are very happy to have Larry join the organization” said A. Mark Schobel, Chief Executive Officer.

Mr. Kranking commented: “I am excited to be joining the MonoSol Rx Team and working on MonoSol Rx’s thin film drug delivery platform. Thin film drug delivery offers patients a unique alternative to conventional dosage forms and over the past three years has established a firm footing in the marketplace.”

About MonoSol Rx LLC
MonoSol Rx is a drug delivery company that uses film as a fast-dissolve oral drug delivery platform. MonoSol Rx LLC’s headquarters are based in Warren, New Jersey and its manufacturing facility is located in Portage, Indiana. MonoSol Rx's film oral dosage form looks like a postage stamp and dissolves readily on the tongue to deliver drugs to a patient, replacing the use of conventional tablets and capsules. MonoSol Rx currently markets a variety of products together with its marketing partners.

Please complete this form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing info@aquestive.com or by calling 1-908-561-1900.

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

  • To subscribe to receive marketing updates about diazepam buccal film and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

  • To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete this form:

  • To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing clinicaltrials@aquestive.com.

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.